**October 2020** – Moderna : “We feel a special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible. **Accordingly, while the pandemic continues, Moderna will not enforce our COVID-19 related patents against those making vaccines intended to combat the pandemic.** Further, to eliminate any perceived IP barriers to vaccine development during the pandemic period, upon request we are also willing to license our intellectual property for COVID-19 vaccines to others for the post pandemic period. ” https://investors.modernatx.com/news-releases/news-release-details/statement-moderna-intellectual-property-matters-during-covid-19
May 2021 – BioNTech: “We have now scaled the manufacturing capacity up to 3 billion doses in 2021, and more than 40% of these doses are expected to go to middle- and low-income countries,” Sahin said.
Waiving patents would not ease supply shortages in the coming months, he said, citing the complexity of producing the mRNA-based shot his company developed last year.
Sahin said his company is working to further expand its manufacturing network with its own sites, such as one now planned in Singapore, and through cooperation with other manufacturers to ensure greater supply while maintaining the quality of the vaccine. But he also noted that rival manufacturers have their own shots either on the market already or in the pipeline.
“We believe, together with the other vaccine developers, in the next 9 to 12 months, that there will be more than enough vaccine produced and there is absolutely no need for waiving patents,” he said.
4 comments
Wtf, EU…
**October 2020** – Moderna : “We feel a special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible. **Accordingly, while the pandemic continues, Moderna will not enforce our COVID-19 related patents against those making vaccines intended to combat the pandemic.** Further, to eliminate any perceived IP barriers to vaccine development during the pandemic period, upon request we are also willing to license our intellectual property for COVID-19 vaccines to others for the post pandemic period. ” https://investors.modernatx.com/news-releases/news-release-details/statement-moderna-intellectual-property-matters-during-covid-19
May 2021 – BioNTech: “We have now scaled the manufacturing capacity up to 3 billion doses in 2021, and more than 40% of these doses are expected to go to middle- and low-income countries,” Sahin said.
Waiving patents would not ease supply shortages in the coming months, he said, citing the complexity of producing the mRNA-based shot his company developed last year.
Sahin said his company is working to further expand its manufacturing network with its own sites, such as one now planned in Singapore, and through cooperation with other manufacturers to ensure greater supply while maintaining the quality of the vaccine. But he also noted that rival manufacturers have their own shots either on the market already or in the pipeline.
“We believe, together with the other vaccine developers, in the next 9 to 12 months, that there will be more than enough vaccine produced and there is absolutely no need for waiving patents,” he said.
https://apnews.com/article/europe-coronavirus-vaccine-coronavirus-pandemic-health-business-2a03ff6d794f6e6b92a58c1403683e7b
There are more than 125000 (USD)millionaires in Africa. Tax them.